[ACOR] Acorda Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.15 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ACOR

Refresh chart

Strongest Trends Summary For ACOR

ACOR is in the long-term down -69% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding46.07 M EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.8% Sales Growth - Q/Q-15.29% P/E-14.87
P/E To EPS Growth P/S2.74 P/BV2.1 Price/Cash Per Share3.83
Price/Free Cash Flow16.48 ROA1.26% ROE2.53% ROI1.53%
Current Ratio3.47 Quick Ratio3.09 Long Term Debt/Equity0.96 Debt Ratio0.22
Gross Margin80.15% Operating Margin7.54% Net Profit Margin3.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.63 M Cash From Investing Activities-116.04 M Cash From Operating Activities-9.25 M Gross Profit90.84 M
Net Profit1000 K Operating Profit5.69 M Total Assets1.1 B Total Current Assets408.31 M
Total Current Liabilities460.01 M Total Debt292.68 M Total Liabilities540.27 M Total Revenue113.71 M
Technical Data
High 52 week32.6 Low 52 week13.8 Last close32.6 Last change7.24%
RSI96.12 Average true range1.73 Beta1.06 Volume622.39 K
Simple moving average 20 days27.01% Simple moving average 50 days34.29% Simple moving average 200 days35.16%
Performance Data
Performance Week23.72% Performance Month38.14% Performance Quart27.34% Performance Half57.11%
Performance Year92.9% Performance Year-to-date51.98% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.76% Volatility yearly44.18% Relative Volume329.71% Average Volume497.09 K
New High New Low

News

2019-06-26 18:17:10 | Pacira Gets EMA Acceptance for Pain Management Drug Exparel

2019-06-26 08:42:12 | Revance Therapeutics RVNC Jumps: Stock Rises 5.2%

2019-06-26 06:11:10 | Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

2019-06-26 06:07:10 | Conatus' Emricasan Lags Primary Goal in Liver Function Study

2019-06-25 08:00:12 | Alnylam Presents New Data for RNAi Therapeutic Onpattro

2019-06-24 17:53:09 | Epizyme Announces Positive Interim Data on Lead Candidate

2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

2019-06-24 11:04:03 | BioMarin Gets $15M From Pfizer on Talzenna's European Nod

2019-06-24 10:05:02 | Vertex's VRTX Symdeko Gets FDA Nod for Use in Children

2019-06-21 11:05:03 | Alexion's sBLA for Ultomiris Gets Priority Review From FDA

2019-06-20 15:31:12 | Here’s What Hedge Funds Think About Acorda Therapeutics Inc ACOR

2019-06-20 09:35:01 | Akari AKTX Eye Candidate Proves Safety in Early-Stage Study

2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH

2019-06-19 09:40:01 | Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

2019-06-19 08:40:12 | Autolus Therapeutics AUTL in Focus: Stock Moves 8.5% Higher

2019-06-18 10:38:02 | Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

2019-06-18 10:27:02 | Protalix PLX Completes Enrollment in Fabry Disease Study

2019-06-18 08:50:12 | Five Prime Therapeutics FPRX Looks Good: Stock Adds 9.2% in Session

2019-06-18 08:02:08 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-06-17 18:17:10 | Alexion's ALXN PNH Drug Ultomiris Shows Long-Term Efficacy

2019-06-14 17:25:09 | Dr. Reddy's Inks Deal to Sell Neurology Branded Products

2019-06-13 17:46:09 | Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

2019-06-13 10:26:02 | NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

2019-06-13 10:15:02 | Acorda Therapeutics Enters Oversold Territory

2019-06-12 10:30:02 | Denali's Hunter Syndrome Candidate Gets Orphan Drug Status

2019-06-10 18:06:10 | Athenex Rallies on Positive Early Data on Psoriasis Candidate

2019-06-06 10:33:02 | BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

2019-06-06 10:29:02 | Reata's RETA Kidney Candidate Gets Orphan Drug Status

2019-06-05 09:02:01 | Myriad Genetics Announces Study Results Of myRisk Cancer Test

2019-06-04 17:30:09 | Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR

2019-06-04 11:52:03 | Emergent EBS Wins HHS Contract to Supply VIGIV Product

2019-06-04 10:26:02 | Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

2019-06-04 08:04:33 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-06-03 07:00:00 | Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress

2019-06-01 09:31:01 | Acorda ACOR Down 11.3% Since Last Earnings Report: Can It Rebound?

2019-06-01 08:02:50 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-05-31 10:46:02 | Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

2019-05-30 16:51:08 | Mesoblast Starts Rolling BLA Submission for Remestemcel-L

2019-05-30 08:50:12 | Chiasma CHMA Catches Eye: Stock Jumps 9.7%

2019-05-29 08:40:12 | Fate Therapeutics FATE Surges: Stock Moves 6.8% Higher

2019-05-28 11:25:03 | REGENXBIO RGNX Catches Eye: Stock Jumps 7.4%

2019-05-23 09:06:00 | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

2019-05-23 07:00:00 | Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference

2019-05-09 11:23:01 | Is Acorda Therapeutics Inc ACOR A Good Stock To Buy?

2019-05-07 08:04:06 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-05-04 16:23:33 | Acorda Therapeutics ACOR Q1 2019 Earnings Call Transcript

2019-05-02 18:55:54 | Edited Transcript of ACOR earnings conference call or presentation 2-May-19 12:30pm GMT

2019-05-02 11:44:03 | Acorda ACOR Earnings and Revenues Beat Estimates in Q1

2019-05-02 08:16:16 | The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

2019-05-02 07:30:11 | Acorda Therapeutics ACOR Reports Q1 Loss, Tops Revenue Estimates